文献速递核素与放射性配体治疗放射性药物与辐射防护

使用[99mTc]Tc-戊柔肽在原发性醛固酮增多症中进行C-X-C趋化因子受体4靶向闪烁显像的验证性研究

C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [99mTc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study.
PubMed 文献 · J Nucl Med · 2024-10-01

该研究回顾性评估了6例原发性醛固酮增多症患者使用新型CXCR4配体[99mTc]Tc-戊柔肽进行CXCR4靶向闪烁显像的可行性。注射后30、120和240分钟行平面显像和SPECT/CT,计算病灶与对侧比值(LCR)。3例显示肾上腺示踪剂摄取侧化,平均最大LCR为1.65(范围1.52-1.70),与CT形态学发现相关;1例接受肾上腺切除术后随访达到完全生化和临床缓解,组织病理学证实为单侧醛固酮生成腺瘤。结论认为该显像在PA患者中可行,可能为[68Ga]Ga-戊柔肽PET的CXCR4靶向显像提供有价值的替代方案。

要点

  • 在6例原发性醛固酮增多症患者中,[99mTc]Tc-戊柔肽SPECT/CT显像可行。
  • 3例显示肾上腺示踪剂摄取侧化,平均最大LCR为1.65(范围1.52-1.70)。
  • 1例术后病理证实单侧醛固酮生成腺瘤,随访达完全生化和临床缓解。

核心结论

  • 在原发性醛固酮增多症患者中,使用[99mTc]Tc-戊柔肽进行SPECT显像是可行的,可能为[68Ga]Ga-戊柔肽PET的CXCR4靶向显像提供有价值的替代方案。

研究设计与样本

  • 回顾性评估6例原发性醛固酮增多症患者(平均年龄±标准差49±15岁),注射435±50 MBq [99mTc]Tc-戊柔肽后30、120和240分钟行平面显像和SPECT/CT,计算病灶与对侧比值(LCR),并与临床信息、组织病理学和临床随访(作为参考标准)进行相关性分析。

主要发现

  • 3例受试者显示肾上腺示踪剂摄取侧化,平均最大病灶与对侧比值为1.65(范围1.52-1.70),与CT形态学发现相关。
  • 1例接受肾上腺切除术,随访时呈现完全生化和临床缓解,组织病理学检查证实为单侧醛固酮生成腺瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

C-X-C motif chemokine receptor 4 (CXCR4)-directed imaging has gained clinical interest in aiding clinical diagnostics in primary aldosteronism (PA). We retrospectively evaluated the feasibility of CXCR4-directed scintigraphy using the novel CXCR-4 ligand [99mTc]Tc-pentixatec in patients with PA. Methods: Six patients (mean age ± SD, 49 ± 15 y) underwent CXCR4-directed scintigraphy (including planar imaging and SPECT/CT) 30, 120, and 240 min after injection of 435 ± 50 MBq of [99mTc]Tc-pentixatec. Adrenal CXCR4 expression was analyzed by calculating lesion-to-contralateral ratios (LCRs). Imaging results were correlated to clinical information. Histopathology and clinical follow-up served as the standard of reference. Results: Three subjects showed lateralization of adrenal tracer accumulation, with a mean maximum lesion-to-contralateral ratio of 1.65 (range, 1.52-1.70), which correlated with morphologic findings on CT. One individual underwent adrenalectomy and presented with complete biochemical and clinical remission at follow-up. Histopathologic workup confirmed unilateral aldosterone-producing adenoma. Conclusion: [99mTc]Tc-pentixatec scintigraphy with SPECT in patients with PA is feasible and might offer a valuable alternative to CXCR4-directed imaging with [68Ga]Ga-pentixafor PET.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Enke JS, Ritzel K, Asbach E, et al. C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [99mTc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study. J Nucl Med. 2024. PMID: 39237344. doi:10.2967/jnumed.124.268169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。